Founded in September 2016, China Liver Health is a national social service non-governmental organisation with independent legal person status approved by the Ministry of Civil Affairs of China. As the only national social service organisation in the field of liver health in China, CLH builds a cooperation platform for relevant experts, institutions and specialists to carry out public welfare activities and jointly contribute to raising public awareness of liver heath, promoting prevention and standardised treatment of liver disease, reducing the burden of disease and eliminating social discrimination against hepatitis patients.
Key activities:
1.Liver health-improving activities for the masses. Work in concert with medical schools, professional associations, foundations, research institutes, medical institutions, and pharmaceutical companies.
2.Matching the needs of doctors, patients, and medical institutions. Organise and mobilise volunteers in the media, education, medical care, and relief fields to carry out liver health science education, training and exchange, immunisation prevention, patient rehabilitation, public assistance, and media publicity.
3.Promote scientific research on the prevention, treatment, and rehabilitation of liver disease at the primary level. Under the guidance of authoritative liver disease experts, conduct professional training and technical consultation, strengthen academic exchanges, and promote international cooperation.
4.Collaborate with medical institutions and specialists to carry out patient services. Through online and offline services, we provide education, observation, and treatment follow-up to patients and establish a sustainable patient management system. Under the guidance of the Ministry of Civil Affairs, the National Health Commission, the Chinese CDC, and the World Health Organization.
5.CLH carry out policy advocacy and undertake international and domestic projects.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close